“Chinese pet drug companies are embarking on the road of innovation and constantly exploring new possibilities!”

In the context of the continuous expansion of the pet market and consumers’ increasing concern for pet health, pet drugs The industry has ushered in unprecedented development opportunities. More and more Chinese pet drug companies have begun to increase investment in research and development, strengthen technological empowerment, and actively develop market innovation products. This action has injected new impetus into the sustainable development of the industry.

< /p>

01

Bolaideli’s world’s first

canine serum albumin injection is launched

Yuanzhihui’s global pet industry overseas insights It was learned that on December 27, the BJSAVA (Beijing Small Animal Diagnosis and Treatment Industry Association) year-end presentation and the launch conference of BJSAVA Dog Serum Albumin Injection was grandly held in Beijing.

At the meeting, the executive vice president and secretary-general of the Chinese Veterinary Medical Association and the chairman of Taizhou Bolideli Biotechnology Co., Ltd. jointly launched the launch ceremony of the new product launch of Boshengjian®. This marks the official launch of the world's first and national first-class new veterinary drug "Boshengjian" canine albumin injection.

Data map: BJSAVA, BJSAVA, the same below

In order to celebrate the product launch, promote industry learning, exchange opportunities and market applications, at this launch conference, BJSAVA Deli is also cooperating with the Chinese Veterinary Medical Association and the Pet Diagnosis and Treatment Branch of the Chinese Veterinary Medical Association to organize the "Didi Vitality Renewal" - the 2024 "Boshengjian Cup" Canine Serum Albumin Clinical Application Case Competition.

It is understood that canine serum albumin is a protein biological product extracted from the plasma of healthy dogs. It has physiological functions such as maintaining plasma osmotic pressure, transporting nutrients, and removing metabolic waste. When dogs are sick or malnourished, albumin synthesis will be affected, resulting in a decrease in albumin levels and affecting the pet's health. At this time, supplementing exogenous albumin becomes a necessary treatment method.

As a pet drug, canine albumin injection is mainly used to treat canine hypovolemia and canine hypoalbuminemia. The main component of this drug is canine albumin, which is injected intravenously or intravenously with an appropriate diluent (such as 5% glucose injection or sodium chloride injection). The daily dosage is determined according to the dog's weight. In clinical practice, veterinarians will use double the dosage at their discretion based on the actual situation.

It is worth noting that no obvious adverse reactions were found when using this drug, but its use still needs to be based on the advice and guidance of a doctor.

The launch of Boshengjian Dog Albumin Injection, a subsidiary of Bolideli, shows that the company has achieved positive results in the development and promotion of a new type of veterinary drug, Canine Albumin Injection. , providing a new treatment method for the pet medical field; and for consumers, it also means that there will be more choices to better care for their pets.

Main information about Boshengjian Canine Albumin Injection↓

◾ Common name: Canine Albumin Injection

◾ Product name: Boshengjian

◾ Main ingredients/content: canine serum albumin, content 100mg/ml

◾ Product properties: slightly viscous, yellow or yellow-green to brown clear liquid

◾ Product function: Used for the treatment of canine hypovolemia and canine hypoalbuminemia

◾ Instructions for use: Intravenous injection or appropriate dilution with 5% glucose injection or sodium chloride injection After intravenous infusion; the daily dosage for dogs is 200mg per 1kg of body weight. Use it as appropriate according to the severity of the condition or follow the doctor's advice

◾ Adverse reactions: No obvious adverse reactions have been seen when used according to the prescribed usage and dosage

◾ Product packaging: 10 bottles/box

◾ Product validity: 24 months

02< /p>

Five years of intensive cultivation, making progress while maintaining stability

Bolaideli focuses on pet drug innovation

Yuanzhihui Global Pet Industry Overseas Insights reviewed relevant information and learned that, Bolaidli was founded in 2009. The company established Taizhou Bolaidli Biotechnology Co., Ltd. in 2018. In the early stages of development, it established a research and development and production project for pet oral liquid and eye drops.

As a research and development manufacturer of veterinary drugs, the company currently specializes in blood protein products for pet prevention, treatment and health care, genetically engineered expression protein drugs, biochemical drug preparations and pet vaccines and other biological drugs and pharmaceutical preparations. and functional health care product development and production.

The following is the development process of "Canine Albumin Injection" under Bolaidli:

In December 2018, it obtained the national Class I new veterinary drug registration certificate, with a monitoring period of 5 years;

Data map: Ministry of Agriculture and Rural Affairs Announcement No. 94

In December 2023, the veterinary drug product approval number was obtained from the Ministry of Rural Affairs of the Ministry of Rural Affairs, and the validity period is December 15, 2023. Date to December 14, 2028.

Data map: Bolaidli

Not only canine serum albumin injection, in August 2023, among the first batch of domestic cat triple vaccine approvals, Bolaidli also Passed the emergency evaluation organized by the Ministry of Agriculture and Rural Affairs.

It can be seen that Boladeli’s R&D capabilities in innovative pet drugs have been fully reflected. At the same time, it also shows that Boladeli’s research and development level in the field of pet medical treatment is at the forefront of the industry. , and actively participate in industry exchanges and technical cooperation, promoting the progress of China's pet medical industry.

Data map: Ministry of Agriculture and Rural Affairs Announcement No. 701

Because of its strong R&D and technical strength, Taizhou Bolaidli Biotechnology Co., Ltd. has attracted a lot of investment so far. those paying attention. According to Aiqicha’s data, from 2019 to 2022, the company has received angel round, Series A, and Series B financing.

< /p>

03

Summary of the development of the pet drug industry in 2023

For the Chinese pet drug industry, 2023 is a very important year. During this year, domestic pet drug companies have made significant progress.

On the one hand, domestic pet drug companies have made major breakthroughs in research and development and innovation. For example, Bolideli's canine serum albumin injection is on the market, many companies such as Hisun Animal Health and Keqian Biotech have obtained approval for cat triple vaccines, and other companies have launched multiple treatment areas such as deworming, anti-infection, and anti-inflammation. New veterinary drugs, these products further enrich the product line of domestic pet drugs.

On the other hand, domestic pet drug companies have also made important progress in market expansion. Yuanzhihui’s global pet industry overseas insights have observed that many domestic pet drug companies have begun to strengthen market promotion and channel construction. They continue to improve the market share and competitiveness of their products by participating in industry exhibitions, strengthening cooperation with pet hospitals, and increasing brand awareness. At the same time, some companies are also actively exploring overseas markets and pushing domestic pet drugs to the global stage.

In general, with the continuous innovation of technology and the continuous expansion of the market, it is believed that domestic pet drug companies will continue to maintain the momentum of rapid development and contribute more to the future development of China's pet drug industry.